China's middle class is estimated to grow from 250 million people in 2003 to over 600 million people in 2020.  As the number of affluent citizens continues to increase, the demand grows for more modern and more readily available healthcare products.

Bridgetech is a leader in the transfer of Western technology to China in the fields of oncology and women's health. With operations both in China and the U.S., Bridgetech is able to leverage the most current medical technology, including drugs, devices and diagnostics, for distribution throughout China.

Bridgetech has longstanding relationships with leading healthcare organizations both in the U.S and China and close ties to government, regulatory and business communities in both countries.  Through these relationships, market demand and local operations, Bridgetech is able to meet China's growing healthcare needs.